Most sleep clinicians know the evidence for slow-paced breathing. Fewer have found a practical way to get patients to actually do it consistently, in the dark, without reaching for their phone. That gap is what moonbird was designed to close.
Moonbird is a handheld tactile breath pacer: it expands and contracts in the hand, guiding slow breathing through touch rather than sound or screen. No blue light, no app required, no gamification. A peer-reviewed pilot study published in Frontiers in Digital Health tested whether that simplicity translates into real clinical benefit for adults with insomnia. The short answer: it does, at least as a first signal.
Moonbird has also developed moonbuddy, a tactile breath pacer designed for children. Moonbuddy came about organically: parents reported that their children were already reaching for the moonbird device to calm down. That insight led to a dedicated version, now actively used in Belgian hospitals. The goal is simple: to give children a way to learn to work with their breathing from an early age. No clinical research on moonbuddy has been published to date.
Why breathing, and why now
The physiological case for slow-paced breathing in insomnia is well established. Breathing at 4–10 cycles per minute activates the parasympathetic nervous system, raises heart rate variability, and shifts the body out of the hyperarousal state that keeps insomnia patients awake. The AASM formalized this in its 2021 updated clinical practice guidelines, which include breathing exercises as a recommended intervention for chronic insomnia disorder in adults.
The challenge has always been adherence. Most breathing guidance tools use visual cues on a screen or audio prompts through earbuds. Both require technology in the bedroom, and both place a cognitive demand on a patient who is already struggling to quiet their mind. Tactile guidance through a physical device sidesteps both problems, but until recently there was little usability data to support it.
What the study did
LiCalab, the Living & Care Lab at Thomas More University of Applied Sciences in Belgium, recruited 39 adults with chronic insomnia (26 female, 13 male; mean age 43 years) and asked them to use the moonbird device at their own discretion over four weeks. No training schedule was imposed. Participants used it when they needed it, mostly for sleep onset difficulties in the evening, but also for nocturnal awakenings and daytime stress.
Sleep quality was assessed before and after using the validated Pittsburgh Sleep Quality Index (PSQI) and the Non-Restorative Sleep Scale (NRSS). All participants entered the study with a PSQI above 5, confirming clinically relevant sleep impairment. Sixteen were already using sleep medication. The study was approved by the Ethical Committee of Antwerp University Hospital (ref. 20/26/345).
What the results showed
After one month, PSQI total scores dropped from 11.28 to 8.27, a statistically significant improvement (p < .001) that meets the proposed Minimum Clinically Important Difference of 3 points for the scale. Participants fell asleep faster, reported better sleep quality, slept longer, and functioned better during the day. Habitual sleep efficiency and use of sleep medication did not change significantly over the study period.
On the Non-Restorative Sleep Scale, scores also improved significantly, from 36.05 to 41.54 (p < .001). Participants reported waking up more refreshed, experiencing fewer physical symptoms, and managing their days better.
Usability was high. 35 of 39 participants rated the device easy to use, and the majority said they would recommend it to friends or family. The standalone function, which lets the device run without a smartphone, was singled out as particularly valuable for nighttime use.
“Patients frequently tell us they struggle to maintain a breathing practice at night without reaching for their phone. The tactile format removes that barrier. Something physical in the hand is both simpler and more suited to the sleep context than a screen-based guide.”
— Stefanie Broes, PharmD, co-founder, moonbird
What clinicians should keep in mind
This was a pilot study. There was no control group, the sample was small, and all outcome measures were subjective. The PSQI also showed lower-than-expected internal consistency in this sample (Cronbach’s α = 0.584). The authors are clear about this, and so are we: these findings are a promising first signal, not a definitive proof of efficacy.
What the study does establish more confidently is usability and feasibility. Patients used the device consistently, found it practical, and reported meaningful improvements in how they felt. For clinicians looking for a low-risk, drug-free option to suggest alongside or ahead of CBT-I, that combination of simplicity and early evidence is worth noting. Randomized controlled trials with objective sleep measurement are the logical next step.
Source: Moonbird
References
- Vermeylen S, Honinx E, Broes S, Vandenhoudt H, De Witte NAJ. Evaluation of a tactile breath pacer for sleep problems: a mixed method pilot study. Front Digit Health. 2022;4:908159. doi:10.3389/fdgth.2022.908159
- Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255–262. doi:10.5664/jcsm.8986
- Tsai HJ, Kuo TBJ, Lee G, Yang CCH. Efficacy of paced breathing for insomnia: enhances vagal activity and improves sleep quality. Psychophysiology. 2015;52(3):388–396. doi:10.1111/psyp.12333
